Ceftin and Temovate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ceftin (cefuroxime axetil) and Temovate (clobetasol propionate). Common drug interactions include adenocarcinoma among females and oedema peripheral among males.

The phase IV clinical study analyzes what interactions people have when they take Ceftin and Temovate. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Ceftin?

Ceftin has active ingredients of cefuroxime axetil. It is often used in sinusitis. eHealthMe is studying from 4,333 Ceftin users. Check the latest studies of Ceftin.

What is Temovate?

Temovate has active ingredients of clobetasol propionate. eHealthMe is studying from 1,392 Temovate users. Check the latest studies of Temovate.

On Jul, 12, 2026

15 people who take Ceftin and Temovate together, and have interactions are studied.

What are the common drug interactions of Ceftin and Temovate, by gender? *:

female:

Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
Alopecia (absence of hair from areas of the body)
Anaemia (lack of blood)
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Aortic valve incompetence
Arthralgia (joint pain)
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Ascites (accumulation of fluid in the abdominal cavity)
Back pain

male:

Oedema peripheral (superficial swelling)
Actinic keratosis (skin disease due to sun exposure)
Sunburn
Acute respiratory failure
Asthenia (weakness)
Blood albumin decreased
Blood calcium decreased
Confusional state
Decreased appetite
Abasia (inability to walk)

What are the common drug interactions of Ceftin and Temovate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Amenorrhoea (absence of a menstrual period in a woman of reproductive age)
Menometrorrhagia (a condition in which prolonged or excessive uterine bleeding occurs irregularly and more frequently than normal)

20-29:

Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Thrombophlebitis superficial (swelling (inflammation) of a superficial vein caused by a blood clot)

30-39:

n/a

40-49:

Actinic keratosis (skin disease due to sun exposure)
Erythema (redness of the skin)
Oedema peripheral (superficial swelling)
Peripheral t-cell lymphoma unspecified (peripheral t-cell cancer unspecified)
Pyoderma (any skin disease that is pyogenic)
General physical health deterioration (weak health status)
Mycosis fungoides (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin)
Sunburn
Acute respiratory failure
Asthenia (weakness)

50-59:

Alopecia (absence of hair from areas of the body)
Anaemia (lack of blood)
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Aortic valve incompetence
Arthralgia (joint pain)
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Ascites (accumulation of fluid in the abdominal cavity)
Back pain
Blood glucose decreased

60+:

Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Abdominal pain
Arthralgia (joint pain)
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Ascites (accumulation of fluid in the abdominal cavity)
Back pain
Blood glucose decreased
Bone pain
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Cardiomegaly (increased size of heart than normal)

What are the existing conditions these people have? *

Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 7 people, 46.67%
Metastases To Bone (cancer spreads to bone): 3 people, 20.00%
Stress And Anxiety: 3 people, 20.00%
Breast Cancer: 3 people, 20.00%
B-Cell Type Acute Leukaemia (cancer of the white blood cells): 2 people, 13.33%
Hypersensitivity: 2 people, 13.33%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 1 person, 6.67%
Bone Loss: 1 person, 6.67%
Malignant Neoplasm Progression (cancer tumour came back): 1 person, 6.67%
Urinary Tract Infection: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftin and Temovate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously